SCHEMBL4860039

SCHEMBL4860039

COc1cccc(CNc2nc(C(OC)c3ccccc3)nc3ccccc23)c1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APP P05067 4/20 0.66
MEN1 O00255 5/20 0.62
KMT2A Q03164 5/20 0.62
USP2 O75604 5/20 0.59
CYP1A2 P05177 5/20 0.59
CYP3A4 P08684 5/20 0.59
CYP2D6 P10635 5/20 0.59
TSHR P16473 5/20 0.59
CYP2C19 P33261 5/20 0.59
LMNA P02545 4/20 0.59
MAPK1 P28482 4/20 0.59
CLK4 Q9HAZ1 3/20 0.59
CYP2C9 P11712 3/20 0.59
ALDH1A1 P00352 1/20 0.59
HSD17B10 Q99714 1/20 0.59
SMN1; SMN2 Q16637 2/20 0.57
MAPT P10636 1/20 0.57
ACP1 P24666 1/20 0.52
SLC2A1 P11166 1/20 0.49
TP53 P04637 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4930371 0.91 APP (0.54) APPMEN1KMT2AUSP2CYP1A2
SCHEMBL5104553 0.88 APP (0.67) APPMEN1KMT2AUSP2CYP1A2
SCHEMBL4867665 0.88 APP (0.64) APPMEN1KMT2AUSP2CYP1A2
SCHEMBL4863323 0.87 APP (0.71) APPMEN1KMT2AUSP2CYP1A2
SCHEMBL4864516 0.85 APP (0.66) APPMEN1KMT2ACYP1A2CYP3A4
SCHEMBL5100498 0.83 CYP1A2 (0.53) APPMEN1KMT2AUSP2CYP1A2
SCHEMBL5102203 0.83 CYP1A2 (0.64) MEN1KMT2AUSP2CYP1A2CYP3A4
SCHEMBL4866281 0.83 APP (0.52) APPMEN1KMT2AUSP2CYP1A2
SCHEMBL4863914 0.83 CYP1A2 (0.48) APPMEN1KMT2AUSP2CYP1A2
SCHEMBL4867976 0.81 APP (0.76) APPMEN1KMT2AUSP2CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080207614-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY SK CHEMICALS CO., LTD. (KR) 2008-08-28 US claimed
JP-2008526734-A 2008-07-24 JP claimed
EP-1844023-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY SK CHEMICALS CO., LTD. (KR) 2007-10-17 EP claimed
WO-2006071095-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY SK CHEMICALS CO., LTD. (KR) 2006-07-06 WO claimed
US-20080207614-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY SK CHEMICALS CO., LTD. (KR) 2008-08-28 US disclosed
EP-1844023-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY SK CHEMICALS CO., LTD. (KR) 2007-10-17 EP disclosed
WO-2006071095-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY SK CHEMICALS CO., LTD. (KR) 2006-07-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080207614-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY GPR119, GCKR, GLP1R APP 4386/4885MEN1 3837/4885KMT2A 1662/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.